Is Celldex Therapeutics (CLDX) Undervalued On Its Latest Earnings Report?

What Celldex’s latest earnings tell you

Celldex Therapeutics (CLDX) just posted third quarter 2026 results that keep the focus on its development pipeline, with revenue still minimal and losses reflecting the costs of antibody research.

The biotech reported a third quarter net loss of US$75.56 million, with basic and diluted loss per share from continuing operations of US$0.96. For the same period a year earlier, net loss was US$67.04 million and loss per share was US$1.01.

Across the first nine months of 2026, Celldex recorded revenue of US$0.037 million and a net loss of US$227.75 million. Basic and diluted loss per share from continuing operations came in at US$3.06, compared with US$2.67 over the prior year period.

This profile is common for early commercial stage drug developers, where limited sales sit next to heavy spending on trials. For you as an investor, the key questions are how long the company can sustain this burn and what potential future products might justify it.

Recent trading has been rough for Celldex Therapeutics. The share price is down 32.22% over 90 days and 7.10% over the past month, including a 5.55% drop to US$28.27 after these earnings. However, the 1 year total shareholder return of 23.45% and 3 year total shareholder return of 4.94% show that longer term holders have still seen gains even as shorter term momentum has clearly faded.

Compare Celldex Therapeutics with a curated group of peers by scanning 34 healthcare AI stocks, which are also pouring cash into research while trying to balance risk and long term potential.

Celldex Therapeutics now trades at a steep discount to both analyst targets and estimated fair value after that 32% slide. Is the market simply cautious about cash burn, or overly harsh on the pipeline story?

Most Popular Narrative: 55% Undervalued

Celldex Therapeutics closed at US$28.27, while the most followed narrative anchors fair value at US$63.07. This highlights a wide gap between the current price and that story driven estimate.

The current valuation implies that the market already prices in meaningful CSU revenue potential and a transition from development stage losses toward future commercial cash generation, yet still leaves room for upside if barzolvolimab’s efficacy and franchise optionality are fully reflected in the share price.

See why 1 investors see Celldex Therapeutics as 55% undervalued.

Result: Fair Value of $63.07 (UNDERVALUED)

Still, the Celldex Therapeutics story could easily shift if barzolvolimab stumbles in new indications or if ongoing heavy losses force highly dilutive fundraising.

Find out about the key risks to this Celldex Therapeutics narrative.

Next Steps

If the mix of risks and potential rewards around Celldex Therapeutics feels finely balanced, do not let the market make the decision for you. Take a few minutes to weigh both sides by reviewing the full breakdown of 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Celldex Therapeutics?

You have seen how one biotech story can swing. Now put that context to work by scanning a wider field of opportunities before you commit fresh capital.

• Target candidates with clean finances by reviewing our list of solid balance sheet and fundamentals (24 results), which combines balance sheet strength with underlying business fundamentals.
• Explore potential mispricings by scanning the 42 high quality undervalued stocks, filtered for quality businesses trading below their assessed worth.
• Prioritise stability and income by checking the 6 dividend fortresses, focused on companies offering higher yield while aiming to keep payouts supported.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com